共 60 条
Two separate effects contribute to regulatory T cell defect in systemic lupus erythematosus patients and their unaffected relatives
被引:21
作者:
Costa, N.
[1
]
Marques, O.
[2
]
Godinho, S. I.
[1
]
Carvalho, C.
[2
]
Leal, B.
[2
]
Figueiredo, A. M.
[2
]
Vasconcelos, C.
[3
]
Marinho, A.
[3
]
Moraes-Fontes, M. F.
[1
,4
]
Gomes da Costa, A.
[5
]
Ponte, C.
[5
]
Campanilho-Marques, R.
[5
,6
]
Coias, T.
[5
]
Martins, A. R.
[7
]
Viana, J. F.
[7
]
Lima, M.
[3
]
Martins, B.
[2
]
Fesel, C.
[1
]
机构:
[1] Inst Gulbenkian Ciencias, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal
[2] Univ Porto, ICBAS, UMIB, Oporto, Portugal
[3] Hosp Santo Antonio, Ctr Hosp Porto, Unidade Imunol Clin, Oporto, Portugal
[4] Hosp Curry Cabral, Ctr Hosp Lisboa Cent, Unidade Doencas Autoimunes, Lisbon, Portugal
[5] Hosp Santa Maria, Lisbon, Portugal
[6] Inst Portugues Reumatol, Lisbon, Portugal
[7] Ctr Hosp Lisboa Ocidental, Lisbon, Portugal
关键词:
cytokines;
regulatory T cells;
systemic lupus erythematosus;
LOW-DOSE INTERLEUKIN-2;
SUPPRESSIVE FUNCTION;
AUTOIMMUNE-DISEASE;
PERIPHERAL-BLOOD;
FOXP3;
EXPRESSION;
IN-VIVO;
SLE;
TH17;
IL-2;
LOCUS;
D O I:
10.1111/cei.12991
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Forkhead box P3 (FoxP3)(+) regulatory T cells (T-regs) are functionally deficient in systemic lupus erythematosus (SLE), characterized by reduced surface CD25 [the interleukin (IL)-2 receptor alpha chain]. Low-dose IL-2 therapy is a promising current approach to correct this defect. To elucidate the origins of the SLE T-reg phenotype, we studied its role through developmentally defined regulatory T cell (T-reg) subsets in 45 SLE patients, 103 SLE-unaffected first-degree relatives and 61 unrelated healthy control subjects, and genetic association with the CD25-encoding IL2RA locus. We identified two separate, uncorrelated effects contributing to T-reg CD25. (1) SLE patients and unaffected relatives remarkably shared CD25 reduction versus controls, particularly in the developmentally earliest CD4(+)FoxP3(+)CD45RO(-)CD31(+) recent thymic emigrant T-regs. This first component effect influenced the proportions of circulating CD4(+)FoxP3(high)CD45RO(+) activated T-regs. (2) In contrast, patients and unaffected relatives differed sharply in their activated T-reg CD25 state: while relatives as control subjects up-regulated CD25 strongly in these cells during differentiation from naive T-regs, SLE patients specifically failed to do so. This CD25 up-regulation depended upon IL2RA genetic variation and was related functionally to the proliferation of activated T-regs, but not to their circulating numbers. Both effects were found related to T cell IL-2 production. Our results point to (1) a heritable, intrathymic mechanism responsible for reduced CD25 on early T-regs and decreased activation capacity in an extended risk population, which can be compensated by (2) functionally independent CD25 up-regulation upon peripheral T-reg activation that is selectively deficient in patients. We expect that T-reg-directed therapies can be monitored more effectively when taking this distinction into account.
引用
收藏
页码:318 / 330
页数:13
相关论文